Harrow Inc. Common Stock (HROW)

FairStock Score: 35/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Harrow, I see a specialty eyecare pharmaceutical business with real revenue growth but no consistent profit. Revenue rose from $130.2M in fiscal 2023 to $272.3M in fiscal 2025, yet net income was -$24.4M, -$17.5M, and -$5.1M in those years. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $70.7M and net income was -$17.3M, a -24.44% margin; fiscal Q1 2026, ended 2026-03-31, showed revenue of $44.2M and a -$27.6M loss. There were profitable quarters, such as fiscal Q2 2025, ended 2025-06-30, with $5.0M net income, and fiscal Q3 2025, ended 2025-09-30, with $1.0M, but those are not enough to offset losses. The FairStock calculations at the 2026-10-13 close of $28.24 show a P/E of -28.53, P/B of 68.88, ROE of -116.07%, ROCE of -0.45%, D/E of 20.26, EV/EBITDA of 112.09, FCF of -$13.1M, and FCF yield of -1.2%. The FairStock Piotroski F-Score is 4/9 and Altman Z-Score is 1.35, which point to weak financial quality. The computed Lynch category is none because the company has lost money in each of the last four years. Without a durable moat or self-funding cash flows, this is a speculative turnaround, not a Graham bargain. The price may look low versus the 52-week range of $27.00-$54.85, but it is expensive versus current earnings, book value, and EBITDA.

In plain English: Harrow is an eyecare drug company that sells compounded and branded eye medicines. Revenue has grown, but the company has lost money in each of the last four years, recent quarters show losses, and cash flow is negative. The stock price looks expensive compared with its current profits and accounting value, so it depends on a future turnaround.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer